| Hetlioz (tasimelteon) / Vanda |
NCT00548340: VEC-162 Study in Adult Patients With Primary Insomnia |
|
|
| Completed | 3 | 322 | US | VEC-162 20 mg, Placebo, VEC-162 50 mg | Vanda Pharmaceuticals | Primary Insomnia | 02/08 | 06/08 | | |
NCT01163032 / 2011-000281-35: Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder |
|
|
| Completed | 3 | 136 | US, Europe | tasimelteon, VEC-162, Placebo | Vanda Pharmaceuticals | Non-24-Hour Sleep-Wake Disorder | 11/12 | 11/12 | | |
NCT01430754: Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder |
|
|
| Completed | 3 | 20 | US | tasimelteon, VEC-162, Placebo | Vanda Pharmaceuticals | Non-24-Hour Sleep-Wake Disorder | 12/12 | 12/12 | | |
NCT01429116 / 2011-004520-35: Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception |
|
|
| Completed | 3 | 200 | US | tasimelteon, VEC-162 | Vanda Pharmaceuticals | Non-24-Hour Sleep-Wake Disorder | 01/15 | 01/15 | | |
